LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Elenco Azioni・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

185.91 -2.06

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

180.91

Massimo

193.2

Metriche Chiave
By Trading Economics
Entrata	262M -15M
Vendite	1.6M 996M
EPS	-0.3
Margine di Profitto	-1.486
Dipendenti	18,300
EBITDA	-11M 187M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+9.77% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	478M 9B
Apertura precedente	187.97
Chiusura precedente	185.91

Notizie sul Sentiment di mercato

By Acuity

29%

71%

71 / 344 Classifica in Healthcare

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 giu 2026, 23:49 UTC

Discorsi di Mercato

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 giu 2026, 23:45 UTC

Acquisizioni, Fusioni, Takeovers

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 giu 2026, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 giu 2026, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 giu 2026, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 giu 2026, 23:35 UTC

Discorsi di Mercato

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 giu 2026, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 giu 2026, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 giu 2026, 20:51 UTC

Utili

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 giu 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 giu 2026, 20:09 UTC

Discorsi di Mercato

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 giu 2026, 19:36 UTC

Discorsi di Mercato

Cattle Climbs as Crude Oil Falls -- Market Talk

9 giu 2026, 19:32 UTC

Discorsi di Mercato

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 giu 2026, 19:25 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 giu 2026, 19:00 UTC

Discorsi di Mercato

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 giu 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 giu 2026, 18:47 UTC

Discorsi di Mercato

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 giu 2026, 18:37 UTC

Discorsi di Mercato

Canada's Cooling Trade With the U.S. -- Market Talk

9 giu 2026, 18:27 UTC

Discorsi di Mercato

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 giu 2026, 17:35 UTC

Discorsi di Mercato

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 giu 2026, 17:30 UTC

Discorsi di Mercato

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 giu 2026, 16:34 UTC

Discorsi di Mercato

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 giu 2026, 16:20 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 giu 2026, 15:28 UTC

Discorsi di Mercato

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 giu 2026, 15:25 UTC

Discorsi di Mercato

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

9.77% in crescita

Previsioni per 12 mesi

Media 208.4 USD 9.77%

Alto 235 USD

Basso 160 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

71 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.